Table 1.

Characteristics of Losartan, Valsartan, and Candesartan Users During the 3-Year Study Period

Drugs and Study Periods
Losartan (March 2010 to February 2013)Valsartan (April 2009 to March 2012)Candesartan (July 2009 to June 2012)
Characteristics
 Age, y777676
 Women, %62.859.661.0
Comorbidities
 All comorbidities, n3.3±2.13.0±2.03.0±2.0
 ≥5 comorbidities, %24.420.020.2
 Cardiovascular comorbidities, n2.5±1.62.3±1.62.3±1.6
 ≥3 cardiovascular comorbidities, %39.534.535.1
 Hypertension, %87.584.086.9
 Ischemic cardiomyopathy, %40.336.636.6
 Heart failure, %14.812.613.0
 Stroke, %11.89.810.5
 Cardiogenic shock, %0.40.40.4
 Diabetes mellitus, %33.429.329.5
 Cardiac arrhythmia, %12.712.012.2
 Acute pulmonary edema, %1.00.90.9
 Renal failure, %12.710.711.6
 Heart valves disease, %6.56.16.3
 Chronic pulmonary obstructive disease, %23.422.521.9
Concomitant drugs
 Nonproprietary name, n10.4±6.69.7±6.49.8±6.3
Socioeconomic status (lowest quintile is favored)
 Lowest quintile of social deprivation, %15.615.615.2
 Highest quintile of social deprivation, %23.523.423.3
 Lowest quintile of material deprivation, %19.516.717.8
 Highest quintile of material deprivation, %21.522.521.0
Region of residence
 Urban (>1.5 million inhabitants), %50.350.347.9
 Rural (<10 000 inhabitants), %19.919.919.6
  • Data are presented as proportions or mean±standard deviations.